a Trastuzumab biosimilar used to treat various types of cancer. The drug will be available in different strengths of 150 mg and 440 mg, according to a regulatory filing by the company. Mamitra is ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...